Brokerages Set Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) PT at $245.94

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has earned a consensus recommendation of “Moderate Buy” from the nineteen analysts that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and sixteen have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $252.8824.

Several equities research analysts have recently weighed in on the company. Leerink Partners increased their price objective on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. TD Cowen upped their price target on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Jazz Pharmaceuticals from $250.00 to $270.00 and gave the stock a “buy” rating in a research note on Thursday. Wells Fargo & Company raised their price objective on shares of Jazz Pharmaceuticals from $250.00 to $265.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Finally, Morgan Stanley restated an “overweight” rating and issued a $245.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, May 7th.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock traded down $3.09 on Tuesday, hitting $243.82. The stock had a trading volume of 630,649 shares, compared to its average volume of 793,956. The stock has a market cap of $15.32 billion, a price-to-earnings ratio of -12,184.91, a P/E/G ratio of 0.22 and a beta of 0.32. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95. Jazz Pharmaceuticals has a 52-week low of $105.00 and a 52-week high of $250.49. The company’s 50 day moving average price is $232.96 and its 200 day moving average price is $198.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The firm had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. On average, research analysts anticipate that Jazz Pharmaceuticals will post 21.9 EPS for the current year.

Insider Activity

In related news, EVP Neena M. Patil sold 1,200 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total transaction of $278,196.00. Following the transaction, the executive vice president owned 51,549 shares of the company’s stock, valued at $11,950,604.67. This trade represents a 2.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Rick E. Winningham sold 2,741 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $241.57, for a total value of $662,143.37. Following the sale, the director directly owned 9,567 shares of the company’s stock, valued at approximately $2,311,100.19. This represents a 22.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 13,098 shares of company stock valued at $3,131,906. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several hedge funds have recently modified their holdings of JAZZ. Royal Bank of Canada raised its position in Jazz Pharmaceuticals by 96.5% during the 1st quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock worth $8,394,000 after buying an additional 33,210 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 147.7% in the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock valued at $43,652,000 after acquiring an additional 209,667 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Jazz Pharmaceuticals by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock valued at $24,479,000 after acquiring an additional 7,954 shares in the last quarter. Focus Partners Wealth boosted its holdings in shares of Jazz Pharmaceuticals by 3.4% in the first quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock valued at $574,000 after acquiring an additional 154 shares in the last quarter. Finally, Geneos Wealth Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 137 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.